ADAP Adaptimmune Therapeutics plc Stock Quote

ADAP [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-1.09	Insider Own	0.07%	Shs Outstand	156.67M	Perf Week	16.31%
Market Cap	254.13M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	-39.15%	Shs Float	88.31M	Perf Month	-14.14%
Income	-170.60M	PEG	-	EPS next Q	-0.25	Inst Own	74.90%	Short Float	5.12%	Perf Quarter	-42.86%
Sales	9.30M	P/S	27.33	EPS this Y	-11.10%	Inst Trans	2.09%	Short Ratio	4.54	Perf Half Y	-60.58%
Book/sh	1.04	P/B	1.58	EPS next Y	-41.40%	ROA	-41.80%	Target Price	6.00	Perf Year	-67.78%
Cash/sh	1.96	P/C	0.84	EPS next 5Y	1.00%	ROE	-76.80%	52W Range	1.26 - 6.86	Perf YTD	-56.27%
Dividend	-	P/FCF	-	EPS past 5Y	-0.10%	ROI	-79.10%	52W High	-76.09%	Beta	2.11
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	-15.40%	Gross Margin	-	52W Low	30.16%	ATR	0.18
Employees	494	Current Ratio	5.40	Sales Q/Q	800.00%	Oper. Margin	-	RSI (14)	47.10	Volatility	12.87% 10.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-31.80%	Profit Margin	-	Rel Volume	0.26	Prev Close	1.67
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 BMO	Payout	-	Avg Volume	996.14K	Price	1.64
Recom	2.70	SMA20	-1.44%	SMA50	-12.98%	SMA200	-54.20%	Volume	263,161	Change	-1.80%

May-28-21

Initiated

Barclays

Underweight

Apr-22-20

Initiated

Mizuho

Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-31-19

Initiated

ROTH Capital

Buy

May-30-19

Resumed

Citigroup

Buy

May-07-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$12 → $5

Mar-17-17

Initiated

Wells Fargo

Market Perform

Oct-24-16

Downgrade

BofA/Merrill

Neutral → Underperform

Sep-30-16

Initiated

Raymond James

Outperform

$16

Feb-25-16

Initiated

Citigroup

Buy

$15

Jun-01-15

Initiated

Leerink Partners

Outperform

$24

Jun-01-15

Initiated

Guggenheim

Buy

Jun-01-15

Initiated

BofA/Merrill

Neutral

May-17-22 05:03PM	Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday Motley Fool +10.56%
May-16-22 05:00PM	Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT GlobeNewswire
May-09-22 07:30AM	Adaptimmune Reports First Quarter Financial Results and Business Update GlobeNewswire -9.94%
May-04-22 08:00AM	Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer GlobeNewswire
Apr-28-22 04:30PM	Adaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022 GlobeNewswire
Apr-26-22 07:24AM	New Strong Sell Stocks for April 26th Zacks -8.16%
Apr-22-22 09:03AM	New Strong Sell Stocks for April 22nd Zacks
Apr-19-22 03:43PM	Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today Motley Fool
Apr-11-22 04:40PM	Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday Motley Fool -14.68%
Apr-08-22 01:00PM	Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors GlobeNewswire
Mar-25-22 07:18AM	New Strong Sell Stocks for March 25th Zacks
Mar-14-22 11:31AM	Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left? Zacks
08:00AM	Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update GlobeNewswire
Mar-08-22 04:14PM	Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal Zacks
12:36PM	Adaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022 GlobeNewswire
Mar-02-22 11:22AM	Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag Zacks
11:16AM	Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss Zacks
10:00AM	After Plunging 19.1% in 4 Weeks, Here's Why the Trend Might Reverse for Adaptimmune Therapeutics PLC (ADAP) Zacks
Feb-24-22 02:49PM	Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag Zacks
Feb-18-22 10:29AM	Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat Zacks
10:15AM	Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-16-22 11:48AM	CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y Zacks
Feb-15-22 12:03PM	Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-01-22 04:11AM	Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders have endured a 48% loss from investing in the stock a year ago Simply Wall St.
Jan-26-22 08:00AM	Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer GlobeNewswire
Jan-19-22 10:15AM	2 Cancer Stocks With Absurdly Low Valuations Motley Fool
Dec-30-21 06:52AM	4 Biotechs That Could Be Potential Takeover Targets in 2022 Zacks
Dec-04-21 04:39PM	Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November Motley Fool
Dec-03-21 04:25AM	Is Adaptimmune Therapeutics (NASDAQ:ADAP) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Dec-01-21 03:27PM	Why Adaptimmune Therapeutics Stock Is Crashing Today Motley Fool -10.84%
Nov-18-21 10:00AM	2 Falling-Knife Stocks Actually Worth Buying Right Now Motley Fool
Nov-12-21 07:00AM	Translational Data at SITC 2021 from Adaptimmunes Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells GlobeNewswire
Nov-11-21 09:00AM	Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS GlobeNewswire -9.09%
Nov-04-21 04:00PM	Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript Motley Fool
07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update GlobeNewswire
Oct-21-21 08:00AM	Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021 GlobeNewswire
Oct-16-21 07:00AM	2 Top Healthcare Stocks That Could Be Bought Out in 2022 Motley Fool
Oct-05-21 08:00AM	Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings GlobeNewswire
Oct-04-21 06:09AM	Could The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ownership Structure Tell Us Something Useful? Simply Wall St.
Sep-27-21 10:08AM	3 Biotech Stocks That Could Make You Filthy Rich Motley Fool
Sep-24-21 08:52AM	Can Adaptimmune (ADAP) Run Higher on Strong Earnings Estimate Revisions? Zacks
Sep-17-21 04:48PM	Why Adaptimmune Therapeutics Was Sinking This Week Motley Fool
Sep-13-21 09:50AM	Adaptimmune Shares Encouraging Data From Solid Tumor Trial Benzinga -6.40%
07:00AM	Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial GlobeNewswire
Sep-08-21 11:39AM	Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More Zacks
10:55AM	Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies Zacks
Sep-07-21 02:32PM	Mid-Afternoon Market Update: Dow Falls Over 200 Points; RenovoRx Shares Spike Higher Benzinga +28.95%
10:16AM	Why Adaptimmune Therapeutics Stock Is Bolting Higher Today Motley Fool
09:08AM	Adaptimmune Stock Moves Higher On Cancer Deal With Genentech Benzinga
07:00AM	Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies GlobeNewswire
03:52AM	Adaptimmune Stock Soars on Roche Pact to Commercialize Cancer Therapy Investing.com
Sep-06-21 10:48AM	Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate Zacks
Sep-05-21 06:15AM	Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit GlobeNewswire
Aug-23-21 01:38PM	Why Adaptimmune Therapeutics Stock Is Spiking Today Motley Fool +12.63%
Aug-16-21 10:05AM	Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock Options Zacks
Aug-09-21 06:30PM	Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Transcript Motley Fool
04:00PM	Adaptimmune Reports Second Quarter Financial Results and Business Update GlobeNewswire
Aug-05-21 01:07AM	If You Had Bought Adaptimmune Therapeutics' (NASDAQ:ADAP) Shares Three Years Ago You Would Be Down 61% Simply Wall St.
Jul-28-21 08:11AM	Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021 GlobeNewswire
Jul-19-21 10:00AM	Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021 Motley Fool
Jun-21-21 10:00AM	2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin Motley Fool
Jun-06-21 03:01AM	Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
May-20-21 05:49PM	Why Adaptimmune Therapeutics Crushed the Market Today Motley Fool
10:15AM	Cancer Biotechs Are on the Move in Advance of Big Conference Barrons.com
May-19-21 05:00PM	Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmunes Phase 2 SPEARHEAD-1 Trial GlobeNewswire
May-11-21 12:32PM	Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows Benzinga
08:00AM	First Preclinical Data from Adaptimmunes Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model GlobeNewswire
May-06-21 07:30AM	Adaptimmune Reports First Quarter Financial Results and Business Update GlobeNewswire
Apr-27-21 04:30PM	Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT GlobeNewswire
Apr-22-21 08:00AM	Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021 GlobeNewswire
Apr-07-21 01:09AM	What Type Of Shareholders Own The Most Number of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares? Simply Wall St. -5.69%
Feb-25-21 07:30AM	Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update GlobeNewswire
06:15AM	Adaptimmune Therapeutics Plc to Host Earnings Call ACCESSWIRE
Feb-11-21 08:00AM	Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 GlobeNewswire
Feb-06-21 01:03AM	Did Adaptimmune Therapeutics' (NASDAQ:ADAP) Share Price Deserve to Gain 52%? Simply Wall St.
Dec-16-20 12:32PM	Is ADAP A Good Stock To Buy Now? Insider Monkey +6.88%
Dec-07-20 11:32PM	We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow Simply Wall St.
Nov-20-20 07:30AM	Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day GlobeNewswire +5.30%
Nov-19-20 09:00AM	Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS GlobeNewswire
Nov-12-20 08:00AM	Adaptimmune to Host Virtual Investor Day on Friday, November 20th GlobeNewswire
Nov-09-20 03:18PM	Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC GlobeNewswire
Nov-08-20 10:00AM	2 Cancer Stocks That Could Make You Filthy Rich Motley Fool
Nov-06-20 11:01AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:30AM	Adaptimmune Reports Q3 Financial Results and Business Update GlobeNewswire
06:15AM	Adaptimmune Therapeutics Plc to Host Earnings Call ACCESSWIRE
Oct-22-20 08:00AM	Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020 GlobeNewswire -5.08%
Oct-16-20 12:41PM	Why Adaptimmune Therapeutics Stock Is Sinking Today Motley Fool -20.13%
Oct-15-20 04:40PM	Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial GlobeNewswire
Oct-13-20 12:04PM	Hedge Funds Have Never Been This Bullish On Adaptimmune Therapeutics plc (ADAP) Insider Monkey +10.05%
Oct-09-20 06:18AM	What Kind Of Shareholders Hold The Majority In Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Shares? Simply Wall St.
Aug-28-20 10:30AM	Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients GlobeNewswire
Aug-11-20 12:00PM	All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to Buy Zacks
Aug-10-20 07:40AM	Announcing: Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Soared An Exciting 367% In The Last Year Simply Wall St.
07:25AM	Did The Underlying Business Drive Adaptimmune Therapeutics' (NASDAQ:ADAP) Lovely 367% Share Price Gain? Simply Wall St.
Aug-06-20 07:30AM	Adaptimmune Reports Q2 Financial Results and Business Update GlobeNewswire -7.57%
Jul-23-20 04:00PM	Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma GlobeNewswire -6.24%
Jul-22-20 08:00AM	Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020 GlobeNewswire
Jul-05-20 02:25PM	Should You Buy Adaptimmune Therapeutics plc (ADAP)? Insider Monkey
Jun-23-20 11:26AM	Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-17-20 09:33AM	Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue? Zacks

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. to develop and commercialize allogeneic cell therapies to treat various oncology indications. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bertrand William C JR	Chief Operating Officer	Jan 18	Sale	3.19	4,368	13,942	7,336	Jan 18 09:04 PM
Lunger John	Chief Patient Supply Officer	Jan 18	Sale	3.19	4,368	13,942	7,336	Jan 18 09:03 PM
Norry Elliot	Chief Medical Officer	Jan 18	Sale	3.19	2,121	6,770	3,529	Jan 18 09:02 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 18	Sale	3.19	11,096	35,416	12,312	Jan 18 09:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12	Sale	3.54	1,076	3,813	1,749	Jan 13 09:02 PM
Norry Elliot	Chief Medical Officer	Jan 12	Sale	3.54	854	3,027	1,383	Jan 13 09:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12	Sale	3.54	3,046	10,795	3,356	Jan 13 09:01 PM
Bertrand William C JR	Chief Operating Officer	Jan 12	Sale	3.54	2,248	7,967	3,754	Jan 13 09:02 PM
Bertrand William C JR	Chief Operating Officer	Jan 11	Sale	3.56	3,770	13,409	6,343	Jan 13 09:02 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 11	Sale	3.56	14,362	51,081	15,978	Jan 13 09:01 PM
Norry Elliot	Chief Medical Officer	Jan 11	Sale	3.56	3,770	13,409	6,343	Jan 13 09:01 PM
Lunger John	Chief Patient Supply Officer	Jan 11	Sale	3.56	3,770	13,409	6,343	Jan 13 09:02 PM
Bertrand William C JR	Chief Operating Officer	Jan 04	Sale	4.06	3,490	14,184	5,873	Jan 05 09:08 PM
Norry Elliot	Chief Medical Officer	Jan 04	Sale	4.06	849	3,451	1,388	Jan 05 09:05 PM
Lunger John	Chief Patient Supply Officer	Jan 04	Sale	4.06	1,070	4,349	1,755	Jan 05 09:06 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 04	Sale	4.06	5,532	22,483	6,172	Jan 05 09:04 PM
Rawcliffe Adrian	Chief Executive Officer	Sep 01	Sale	5.20	2,782	14,452	3,070	Sep 01 09:00 PM
Lunger John	Chief Patient Supply Officer	Aug 02	Sale	3.58	2,939	10,536	4,873	Aug 02 05:09 PM
Rawcliffe Adrian	Chief Executive Officer	Jun 28	Sale	4.37	2,794	12,210	3,058	Jun 28 09:01 PM
Alleva Lawrence M	Director	Jun 01	Buy	0.79	12,600	9,954	12,600	Jun 03 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience